Aquestive Therapeutics (AQST) Short term Debt (2018 - 2025)
Historic Short term Debt for Aquestive Therapeutics (AQST) over the last 8 years, with Q3 2025 value amounting to $6.3 million.
- Aquestive Therapeutics' Short term Debt rose 2520800.0% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 2520800.0%. This contributed to the annual value of $26000.0 for FY2024, which is 1818.18% up from last year.
- Aquestive Therapeutics' Short term Debt amounted to $6.3 million in Q3 2025, which was up 2520800.0% from $3.2 million recorded in Q2 2025.
- Over the past 5 years, Aquestive Therapeutics' Short term Debt peaked at $18.7 million during Q4 2022, and registered a low of $22000.0 during Q4 2023.
- Its 5-year average for Short term Debt is $6.2 million, with a median of $4.6 million in 2023.
- In the last 5 years, Aquestive Therapeutics' Short term Debt tumbled by 9988.24% in 2023 and then soared by 2520800.0% in 2025.
- Over the past 5 years, Aquestive Therapeutics' Short term Debt (Quarter) stood at $2.0 million in 2021, then skyrocketed by 823.46% to $18.7 million in 2022, then plummeted by 99.88% to $22000.0 in 2023, then grew by 18.18% to $26000.0 in 2024, then skyrocketed by 24234.62% to $6.3 million in 2025.
- Its Short term Debt stands at $6.3 million for Q3 2025, versus $3.2 million for Q2 2025 and $27000.0 for Q1 2025.